(Q38509732)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028357%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

review article

1 reference

title

Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028357%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028357%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

Julia C Stingl

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028357%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

author name string

Kristina Probst-Schendzielorz

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028357%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

language of work or name

English

0 references

publication date

1 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028357%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Metabolism & Toxicology

16 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028357%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028357%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028357%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

page(s)

1219-1232

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028357%20AND%20SRC:MED&resulttype=core&format=json

Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism

16 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Understanding the pharmacogenetics of selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Recent examples on the clinical relevance of the CYP2D6 polymorphism and endogenous functionality of CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Applications of CYP450 testing in the clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Clinical consequences of cytochrome P450 2C9 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Functional gene variants of CYP3A4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Clinical applications of CYP genotyping in psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

CYP2C19 variation and citalopram response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Pharmacokinetics of selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Genetic differences in cytochrome P450 enzymes and antidepressant treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Concentrations of the enantiomers of fluoxetine and norfluoxetine after multiple doses of fluoxetine in cytochrome P4502D6 poor and extensive metabolizers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Pharmacogenetics of antidepressant medication intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Severe sleepiness and excess sleep duration induced by paroxetine treatment is a beneficial pharmacological effect, not an adverse reaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Clinical pharmacokinetics of sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Time-dependent inhibition of CYP3A4 by sertraline, a selective serotonin reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

A prospective study of 86 new patients with social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2015.1052791

10.1517/17425255.2015.1052791

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26028357%20AND%20SRC:MED&resulttype=core&format=json

16 February 2020

1 reference